MX2012012031A - Inhibidores de la actividad de la proteina tirosina quinasa y uso de los mismos para tratar transtornos oftalmicos. - Google Patents

Inhibidores de la actividad de la proteina tirosina quinasa y uso de los mismos para tratar transtornos oftalmicos.

Info

Publication number
MX2012012031A
MX2012012031A MX2012012031A MX2012012031A MX2012012031A MX 2012012031 A MX2012012031 A MX 2012012031A MX 2012012031 A MX2012012031 A MX 2012012031A MX 2012012031 A MX2012012031 A MX 2012012031A MX 2012012031 A MX2012012031 A MX 2012012031A
Authority
MX
Mexico
Prior art keywords
tyrosine kinase
protein tyrosine
inhibitors
kinase activity
ophthalmic disorders
Prior art date
Application number
MX2012012031A
Other languages
English (en)
Inventor
Lijie Zhan
Stephen William Claridge
Franck Raeppel
Arkadii Vaisburg
Frederic Gaudette
Stephane Raeppel
Original Assignee
Methylgene Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Methylgene Inc filed Critical Methylgene Inc
Publication of MX2012012031A publication Critical patent/MX2012012031A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides

Abstract

Se describen compuestos y composiciones de los mismos que son inhibidores de la proteína tirosina quinasa; los compuestos encuentran uso en el tratamiento de enfermedades, desórdenes o condiciones oftálmicas; dichos compuestos son de las fórmulas (I), (II) o (III); en donde R = (IV), (y), (VI), (VII), (VIII), (IX), (X), (Xl) o (XII).
MX2012012031A 2010-04-16 2011-04-08 Inhibidores de la actividad de la proteina tirosina quinasa y uso de los mismos para tratar transtornos oftalmicos. MX2012012031A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32480310P 2010-04-16 2010-04-16
PCT/CA2011/000390 WO2011127565A1 (en) 2010-04-16 2011-04-08 Inhibitors of protein tyrosine kinase activity and use thereof to treat ophthalmic disorders

Publications (1)

Publication Number Publication Date
MX2012012031A true MX2012012031A (es) 2012-12-17

Family

ID=44788641

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2012012031A MX2012012031A (es) 2010-04-16 2011-04-08 Inhibidores de la actividad de la proteina tirosina quinasa y uso de los mismos para tratar transtornos oftalmicos.
MX2012012032A MX2012012032A (es) 2010-04-16 2011-04-08 Inhibidores de la actividad de la proteina tirosina quinasa.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2012012032A MX2012012032A (es) 2010-04-16 2011-04-08 Inhibidores de la actividad de la proteina tirosina quinasa.

Country Status (18)

Country Link
US (3) US8455484B2 (es)
EP (2) EP2563795A4 (es)
JP (2) JP2013525286A (es)
KR (2) KR20130100234A (es)
CN (2) CN102947315A (es)
AR (2) AR080871A1 (es)
AU (2) AU2011241420B2 (es)
CA (2) CA2796008A1 (es)
CO (2) CO6630193A2 (es)
EA (2) EA201291052A1 (es)
MX (2) MX2012012031A (es)
MY (1) MY157319A (es)
NZ (2) NZ602954A (es)
SG (2) SG184883A1 (es)
TW (2) TW201204735A (es)
UA (1) UA108878C2 (es)
WO (2) WO2011127567A1 (es)
ZA (2) ZA201207482B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2635131T3 (es) * 2007-08-29 2017-10-02 Methylgene Inc. Inhibidores de la actividad de la proteína tirosina cinasa
US8729268B2 (en) * 2008-03-05 2014-05-20 Methylgene Inc. Inhibitors of protein tyrosine kinase activity
KR20130100234A (ko) * 2010-04-16 2013-09-10 메틸진 인코포레이티드 단백질 티로신 키나아제 활성의 억제 및 안구 질환을 치료하는 이의 용도
WO2013044360A1 (en) * 2011-09-30 2013-04-04 Methylgene Inc. Inhibitors of protein tyrosine kinase activity
WO2013044361A1 (en) * 2011-09-30 2013-04-04 Methylgene Inc. Inhibitors of protein tyrosine kinase activity
WO2013044362A1 (en) * 2011-09-30 2013-04-04 Methylgene Inc. Selected inhibitors of protein tyrosine kinase activity
CA2857603C (en) 2011-12-15 2016-08-02 Pfizer Limited Sulfonamide derivatives
US10544117B2 (en) 2014-09-10 2020-01-28 Temple University—Of the Commonwealth System of Higher Education 5-hydroxytryptamine receptor 7 activity modulators and their method of use
US20180221365A1 (en) * 2015-05-12 2018-08-09 Temple University-Of The Commonwealth System Of Higher Education Novel sigma-2 receptor binders and their method of use
CN108530464B (zh) * 2017-03-02 2020-10-27 深圳海王医药科技研究院有限公司 一种多靶点激酶抑制剂

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050020619A1 (en) * 2003-07-24 2005-01-27 Patrick Betschmann Thienopyridine kinase inhibitors
CN101031570B (zh) * 2004-07-30 2012-09-05 梅特希尔基因公司 Vegf受体和hgf受体信号的抑制剂
AU2006229343A1 (en) * 2005-03-28 2006-10-05 Kirin Pharma Kabushiki Kaisha Thienopyridine derivative, or quinoline derivative, or quinazoline derivative, having c-Met autophosphorylation inhibiting potency
JO2787B1 (en) * 2005-04-27 2014-03-15 امجين إنك, Alternative amide derivatives and methods of use
EP1904504B1 (en) * 2005-05-20 2014-03-19 MethylGene Inc. Inhibitors of vegf receptor and hgf receptor signaling
BRPI0610322B8 (pt) * 2005-05-20 2021-05-25 Methylgene Inc inibidores de sinalização de receptor de vegf e de receptor de hgf e composição farmacêutica
US8907091B2 (en) 2007-08-29 2014-12-09 Methylgene Inc. Processes and intermediates for preparing fused heterocyclic kinase inhibitors
ES2635131T3 (es) * 2007-08-29 2017-10-02 Methylgene Inc. Inhibidores de la actividad de la proteína tirosina cinasa
US8729268B2 (en) * 2008-03-05 2014-05-20 Methylgene Inc. Inhibitors of protein tyrosine kinase activity
KR20130100234A (ko) * 2010-04-16 2013-09-10 메틸진 인코포레이티드 단백질 티로신 키나아제 활성의 억제 및 안구 질환을 치료하는 이의 용도
WO2013044361A1 (en) * 2011-09-30 2013-04-04 Methylgene Inc. Inhibitors of protein tyrosine kinase activity

Also Published As

Publication number Publication date
CN103025740A (zh) 2013-04-03
WO2011127565A1 (en) 2011-10-20
US20140315801A1 (en) 2014-10-23
CN102947315A (zh) 2013-02-27
UA108878C2 (ru) 2015-06-25
WO2011127567A1 (en) 2011-10-20
EP2563794A1 (en) 2013-03-06
EP2563794A4 (en) 2013-12-04
EA201291052A1 (ru) 2013-04-30
TW201204734A (en) 2012-02-01
CO6630193A2 (es) 2013-03-01
US20110257175A1 (en) 2011-10-20
EP2563795A1 (en) 2013-03-06
CN103025740B (zh) 2015-07-01
AU2011241422A1 (en) 2012-11-01
US8906852B2 (en) 2014-12-09
EA201291055A1 (ru) 2013-09-30
AR080875A1 (es) 2012-05-16
MY157319A (en) 2016-05-31
KR20130058006A (ko) 2013-06-03
ZA201207557B (en) 2013-06-26
US20110257100A1 (en) 2011-10-20
CA2796008A1 (en) 2011-10-20
AU2011241420B2 (en) 2015-04-16
JP2013523846A (ja) 2013-06-17
NZ602948A (en) 2014-09-26
NZ602954A (en) 2014-11-28
CO6640224A2 (es) 2013-03-22
KR20130100234A (ko) 2013-09-10
JP2013525286A (ja) 2013-06-20
TW201204735A (en) 2012-02-01
US8455484B2 (en) 2013-06-04
AR080871A1 (es) 2012-05-16
CA2796054A1 (en) 2011-10-20
MX2012012032A (es) 2012-12-17
ZA201207482B (en) 2013-09-25
SG184882A1 (en) 2012-11-29
AU2011241422B2 (en) 2015-05-07
EP2563795A4 (en) 2013-10-23
SG184883A1 (en) 2012-11-29

Similar Documents

Publication Publication Date Title
AU2018236800B2 (en) DNA-PK inhibitors
MX2012012031A (es) Inhibidores de la actividad de la proteina tirosina quinasa y uso de los mismos para tratar transtornos oftalmicos.
MA32393B1 (fr) Composés et compositions servant d'inhibiteurs de kinases
TN2013000348A1 (en) Compounds and compositions as trk inhibitors
PH12015502575B1 (en) Piperidin-4-yl azetidine derivatives as jak1 inhibitors
MX339937B (es) Compuestos y composiciones como inhibidores de la quinasa c-kit.
MX342329B (es) Compuestos y composiciones como inhibidores de la quinasa c-kit.
MX2013011908A (es) Composiciones y usos terapeuticos de inhibidores de cinasa epsilon relacionados con cinasa i-kappa b (ikk) y cinasa 1 de union tank.
TN2012000081A1 (en) Compounds and compositions as protein kinase inhibitors
MX2009011951A (es) Compuestos y composiciones como inhibidores de cinasa c-kit y pdgfr.
MX2013005392A (es) Compuestos de hidroxiamida pirimidina como inhibidores de la proteina deacetilasa y metodo de uso de estos.
EA201391682A1 (ru) Замещенные производные индазола, активные в качестве ингибиторов киназы
MX344479B (es) Derivados de azetidinil fenil, piridil o pirazinil carboxamida como inhibidores de cinasa janus (jak).
EA024842B9 (ru) Соединения в качестве модуляторов протеинкиназы pi3k
MX2014002486A (es) Compuestos y composiciones como inhibidores de cinasa pdgfr.
MX2014010589A (es) Compuestos a base de pirazol[1,5-a]pirimidina, composiciones que los comprenden, y metodos para su uso.
IN2014KN02601A (es)
WO2012037155A3 (en) Tyrosine kinase inhibitors
EA201691032A1 (ru) Производные изохромена в качестве ингибиторов фосфоинозитид-3-киназ
MX2013012661A (es) Compuestos de piridazina biciclicos como inhibidores pim.
MX2009011952A (es) Compuestos y composiciones como inhibidores de cinasa c-kit y pdgfr.
BR112013009260A2 (pt) compostos de carboxamida de piridazina substituídos como compostos inibidores de quinase
UA111520C2 (uk) [1,2,4]триазолопіридини і їх застосування як інгібіторів фосфодіестерази
EA201390532A1 (ru) Композиции сульфамидых ингибиторов ns3, содержащие витамин е
MY198316A (en) Piperidin-4-YL Azetidine Derivatives as JAK1 Inhibitors

Legal Events

Date Code Title Description
FG Grant or registration